Compare ADMA Biologics Inc (ADMA) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Intuitive Surgical, Inc. — how do they compare? ADMA Biologics Inc trades at $9.9 (market cap $2.22B), while Intuitive Surgical, Inc. trades at $399.09 (market cap $141.75B). The key difference: Intuitive Surgical, Inc. is far larger — about 63.9× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.
| ADMA | ISRG | |
|---|---|---|
Market Cap | $2.22B | $141.75B |
Sector | Health | Health |
52-Week High | $20.38 | $592.85 |
52-Week Low | $7.60 | $332.02 |
Enterprise Value | $2.29B | $136.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Intuitive Surgical (ISRG) trades at $393.38, up 3.85% on the day, with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. The stock exhibits premium valuation metrics, including a P/E of 46.01 and P/S of 13.08, supported by robust revenue growth, which reached $10.06B in 2025, and high net income margins of 28.45%. Recent news highlights analyst upgrades and optimism around the da Vinci 5 system's adoption.
The outlook remains positive given durable demand and innovation, but risks include heightened competition and valuation sensitivity. Wall Street consensus is bullish with a $518.10 price target, implying significant upside, though investors should weigh premium multiples against growth sustainability and competitive pressures in the medtech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
